Payment overview · 2025
General Payments
$160.17
8 reported records · 2 companies
Healthcare provider profile · identity verified
Laura E Pica, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DELMAR, NY · NPI 1629060652
Verified facts
What the public records show
CMS Open Payments records show Laura E Pica, M.D. received $160.17 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 89.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.71 | 89.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.46 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $160.17 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.30 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.00 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 573 | 175 |
| Omeprazole | Omeprazole | 503 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 134 |
| Alprazolam | Alprazolam | 348 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 337 | 112 |
| Zolpidem Tartrate | Zolpidem Tartrate | 301 | 57 |
| Lisinopril | Lisinopril | 255 | 78 |
| Famotidine | Famotidine | 208 | 70 |
| Losartan Potassium | Losartan Potassium | 192 | 62 |
| Simvastatin | Simvastatin | 192 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 71 |
| Gabapentin | Gabapentin | 179 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 156 | 38 |
| Bupropion Xl | Bupropion Hcl | 153 | 41 |
| Sertraline Hcl | Sertraline Hcl | 144 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 43 |
| Trazodone Hcl | Trazodone Hcl | 126 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 37 |
| Tramadol Hcl | Tramadol Hcl | 113 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 109 | 39 |
| Metformin Hcl | Metformin Hcl | 108 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 33 |
| Montelukast Sodium | Montelukast Sodium | 102 | 29 |
| Prednisone | Prednisone | 94 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 36 |
| Celecoxib | Celecoxib | 89 | 25 |
| Clonazepam | Clonazepam | 85 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 83 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 25 |
| Furosemide | Furosemide | 77 | 31 |
| Potassium Chloride | Potassium Chloride | 72 | 29 |
| Allopurinol | Allopurinol | 71 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 14 |
| Lorazepam | Lorazepam | 69 | 13 |
| Synthroid | Levothyroxine Sodium | 69 | 20 |
| Alendronate Sodium | Alendronate Sodium | 68 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 25 |
| Valacyclovir | Valacyclovir Hcl | 62 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 56 | 14 |
| Mirtazapine | Mirtazapine | 55 | 11 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Temazepam | Temazepam | 48 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 47 | suppressed |
| Ozempic | Semaglutide | 47 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 15 |
| Amoxicillin | Amoxicillin | 45 | 34 |
| Eliquis | Apixaban | 44 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Irbesartan | Irbesartan | 42 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 41 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 14 |
| Lansoprazole | Lansoprazole | 40 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Azelastine Hcl | Azelastine Hcl | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 17 |
| Diazepam | Diazepam | 34 | 14 |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 12 |
| Risedronate Sodium | Risedronate Sodium | 33 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 20 |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Pulmicort Flexhaler | Budesonide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | 11 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 16 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 15 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Metronidazole | Metronidazole | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $160.17 · 8 records | ABBVIE INC. | QULIPTA, TRELEGY ELLIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error